{"id":"W4220929644","doi":"10.1016/j.ejca.2022.02.009","title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Tolerability; Internal medicine; Adverse effect; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Discontinuation; Gastroenterology; Progression-free survival; Surgery; Oncology; Phases of clinical research; Toxicity; Clinical trial; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004174334,0.000252356,0.0007596464,0.0003055712,0.0001027456,0.000006596464,0.0001471474,0.00001624182,0.0001641736],"category_scores_gemma":[0.00001676252,0.0001754831,0.00007707868,0.0005247121,0.00007625874,0.0001053409,0.00008511308,0.0003143644,3.020283e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00014738,"about_ca_system_score_gemma":0.0001988204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006553577,"about_ca_topic_score_gemma":0.00001249479,"domain_scores_codex":[0.9975376,0.0005225777,0.0008054195,0.0002532685,0.0006433036,0.0002378249],"domain_scores_gemma":[0.9983684,0.00002960431,0.0007924109,0.0002657572,0.0003738659,0.0001699646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05423065,0.005414187,0.91983,0.00006220194,0.0004770443,0.001316372,0.003415861,0.000149828,0.0005890992,7.317574e-7,0.00002961623,0.01448437],"study_design_scores_gemma":[0.1396616,0.08396354,0.7715281,0.0003169323,0.001045824,0.00006522609,0.0005990415,0.0001967227,0.001658197,3.087568e-7,0.00075646,0.0002079591],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964871,0.001844187,0.000007313661,0.00006422411,0.00002878652,0.001362006,0.0000342243,0.000009336389,0.0001628312],"genre_scores_gemma":[0.999589,0.00006467699,0.0001097767,0.00002402437,0.00002384284,0.00001550948,0.00003217344,0.00006119966,0.00007975107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1483019,"threshold_uncertainty_score":0.7155994,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01983071802193114,"score_gpt":0.2446170420919442,"score_spread":0.2247863240700131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}